SCHEMBL6586531

SCHEMBL6586531

CS(=O)(=O)n1cc(-c2cccc(Cl)c2)c2cc(C(=O)c3ccc(Cl)cc3)ccc21

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SCN9A Q15858 3/20 0.41
SCN2B O60939 2/20 0.41
SCN1B Q07699 2/20 0.41
SCN5A Q14524 2/20 0.41
SCN1A P35498 1/20 0.41
SLC9A1 P19634 1/20 0.39
PTGS2 P35354 1/20 0.39
RORC P51449 3/20 0.37
FNTA P49354 3/20 0.36
FNTB P49356 3/20 0.36
CNR1 P21554 1/20 0.36
CNR2 P34972 1/20 0.36
TUBB4A P04350 1/20 0.36
TUBB P07437 1/20 0.36
TUBA3C P0DPH7 1/20 0.36
TUBA1B P68363 1/20 0.36
TUBA4A P68366 1/20 0.36
TUBB4B P68371 1/20 0.36
TUBB3 Q13509 1/20 0.36
TUBB2A Q13885 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1538260 0.78 FNTA (0.56) FNTAFNTB
SCHEMBL30419724 0.78 FNTA (0.56) FNTAFNTB
SCHEMBL5657267 0.73 FNTA (0.54) FNTAFNTBCNR1CNR2
SCHEMBL11561833 0.72 CNR1 (0.56) CNR1CNR2
SCHEMBL7761431 0.72 PTGS2 (0.54) PTGS2POLBMAPT
SCHEMBL6584469 0.72 FNTA (0.72) RORCFNTAFNTB
SCHEMBL6602856 0.72 FNTA (0.35) PTGS2FNTAFNTBPGR
SCHEMBL6602862 0.72 FNTA (0.53) RORCFNTAFNTB
SCHEMBL6861981 0.72 ALDH1A1 (0.42) FNTAFNTBCNR1
SCHEMBL7486522 0.71 SMN1; SMN2 (0.43) FNTAFNTBCNR1CNR2PGR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1420015-A1 Imidazolyl derivatives SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES S.A.S. (FR) 2004-05-19 EP disclosed
EP-1097150-B1 IMIDAZOLYL DERIVATIVES CONSEILS DE RECH SET D APPLIC (FR) 2004-03-24 EP disclosed
US-20040002531-A1 Imidazolyl derivatives SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATION SCIENTEFIQUES, S.A.S., A FRANCE CORPORATION 2004-01-01 US disclosed
US-6509336-B1 Prenyl transeferase inhibitors SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES, S.A.S. (FR) 2003-01-21 US disclosed
US-20030004342-A1 Imidazolyl derivatives BIOMEASURE, INC., A MASSACHUSETTS CORPORATION 2003-01-02 US disclosed
US-6420555-B1 IMIDAZOLE DERIVATIVES PRENYL TRANSFERASE INHIBITORS. SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES, S.A.S. (FR) 2002-07-16 US disclosed
EP-1097150-A1 IMIDAZOLYL DERIVATIVES SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES S.A.S. (FR) 2001-05-09 EP disclosed
WO-1999065898-A1 IMIDAZOLYL DERIVATIVES SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES SAS (FR) 1999-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030004342-A1 Imidazolyl derivatives TPI1, BCHE, CYP51A1 SCN9A 2615/4885SCN2B 3424/4885SCN1B 3319/4885
US-20040002531-A1 Imidazolyl derivatives TPI1, BCHE, CYP51A1 SCN9A 2615/4885SCN2B 3424/4885SCN1B 3319/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.